[1] The Lancet Gastroenterology Hepatology. Obesity: another ongoing pandemic. Lancet Gastroenterol Hepatol. 2021;6(6):411. doi:10.1016/S2468-1253(21)00143-6[2] Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590. doi:10.1016/j.ebiom.2019.11.051[3] Hosomi K, Saito M, Park J, et al. Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. Nat Commun. 2022;13(1):4477. Published 2022 Aug 18. doi:10.1038/s41467-022-32015-7[4] Ozato N, Saito S, Yamaguchi T, et al. Blautia genus associated with visceral fat accumulation in adults 20-76 years of age. NPJ Biofilms Microbiomes. 2019;5(1):28. Published 2019 Oct 4. doi:10.1038/s41522-019-0101-x[5] Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261-273. doi:10.1038/s41574-019-0156-z[6] Sekimoto R, Fukuda S, Maeda N, et al. Visualized macrophage dynamics and significance of S100A8 in obese fat. Proc Natl Acad Sci U S A. 2015;112(16):E2058-E2066. doi:10.1073/pnas.1409480112[7] Zhang S, Zhao J, Xie F, et al. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev. 2021;22(11):e13316. doi:10.1111/obr.13316